CN117264878A - Culture solution added with echinacoside for improving porcine oocyte aging and application thereof - Google Patents
Culture solution added with echinacoside for improving porcine oocyte aging and application thereof Download PDFInfo
- Publication number
- CN117264878A CN117264878A CN202311212065.8A CN202311212065A CN117264878A CN 117264878 A CN117264878 A CN 117264878A CN 202311212065 A CN202311212065 A CN 202311212065A CN 117264878 A CN117264878 A CN 117264878A
- Authority
- CN
- China
- Prior art keywords
- echinacoside
- volume fraction
- culture solution
- porcine
- galactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000287 oocyte Anatomy 0.000 title claims abstract description 111
- 230000032683 aging Effects 0.000 title claims abstract description 39
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 title claims abstract description 36
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 title claims abstract 28
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims abstract description 118
- 239000000243 solution Substances 0.000 claims abstract description 48
- 230000035800 maturation Effects 0.000 claims abstract description 44
- 210000001733 follicular fluid Anatomy 0.000 claims abstract description 42
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 20
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract description 20
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 20
- 102000006771 Gonadotropins Human genes 0.000 claims abstract description 20
- 108010086677 Gonadotropins Proteins 0.000 claims abstract description 20
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 20
- 239000012091 fetal bovine serum Substances 0.000 claims abstract description 20
- 239000002622 gonadotropin Substances 0.000 claims abstract description 20
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 20
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 14
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000007995 HEPES buffer Substances 0.000 claims abstract description 8
- 229960004407 chorionic gonadotrophin Drugs 0.000 claims abstract 4
- 238000000338 in vitro Methods 0.000 claims description 48
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 16
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 16
- 229940015047 chorionic gonadotropin Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 210000000349 chromosome Anatomy 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 210000001771 cumulus cell Anatomy 0.000 claims description 6
- 239000011550 stock solution Substances 0.000 claims description 6
- 210000001672 ovary Anatomy 0.000 claims description 5
- 238000011160 research Methods 0.000 claims description 5
- 239000004201 L-cysteine Substances 0.000 claims description 4
- 235000013878 L-cysteine Nutrition 0.000 claims description 4
- 238000013401 experimental design Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 210000004508 polar body Anatomy 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 2
- 230000018109 developmental process Effects 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 abstract description 3
- 239000001963 growth medium Substances 0.000 description 74
- 235000014134 echinacea Nutrition 0.000 description 25
- 244000133098 Echinacea angustifolia Species 0.000 description 22
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 11
- 229960003067 cystine Drugs 0.000 description 11
- 239000011521 glass Substances 0.000 description 6
- 108010003272 Hyaluronate lyase Proteins 0.000 description 5
- 102000001974 Hyaluronidases Human genes 0.000 description 5
- 229960002773 hyaluronidase Drugs 0.000 description 5
- 239000005662 Paraffin oil Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241000258180 Echinacea <Echinodermata> Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 125000003563 glycoside group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001776 parthenogenetic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 1
- 241000336291 Cistanche deserticola Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000008182 oocyte development Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
技术领域Technical field
本发明涉及一种猪卵母细胞体外成熟培养液,具体为一种添加松果菊苷改善猪卵母细胞老化的培养液及其应用,属于家畜繁殖技术应用领域。The invention relates to an in vitro maturation culture medium for pig oocytes, specifically a culture medium for adding echinacea to improve the aging of pig oocytes and its application, and belongs to the application field of livestock reproduction technology.
背景技术Background technique
猪卵母细胞体外成熟培养(IVM)作为产生猪胚胎的方式之一,是家畜繁殖技术中的重要环节,体外成熟卵母细胞的质量影响了包括体外受精、孤雌激活和胚胎克隆在内的多个技术环节。由于现有的体外培养体系无法完全还原体内微环境,导致体外成熟的卵母细胞比之体内成熟的卵母细胞在成熟率、成熟质量和发育潜能存在明显差异,因此建立一种更稳定,卵母细胞成熟率更高的体外培养体系刻不容缓。Porcine oocyte in vitro maturation culture (IVM), as one of the ways to produce pig embryos, is an important link in livestock reproduction technology. The quality of in vitro mature oocytes affects methods including in vitro fertilization, parthenogenetic activation and embryo cloning. Multiple technical links. Since the existing in vitro culture system cannot completely restore the in vivo microenvironment, oocytes matured in vitro have significantly different maturation rates, maturation quality and developmental potential than oocytes matured in vivo. Therefore, a more stable oocyte is established. An in vitro culture system with a higher mother cell maturation rate is urgent.
目前,体外成熟过程中添加何种有益于卵母细胞发育的核心因子尚不明确,普遍认为有助于卵母细胞成熟的因子包括激素、生长因子、细胞因子和其他组分等。At present, it is not clear what core factors are added during in vitro maturation that are beneficial to oocyte development. It is generally believed that factors that contribute to oocyte maturation include hormones, growth factors, cytokines and other components.
因此,提供一种猪卵母细胞体外成熟培养液及其应用是本领域技术人员亟需解决的问题。Therefore, providing an in vitro maturation culture medium for porcine oocytes and its application is an urgent problem that those skilled in the art need to solve.
D-半乳糖是一种醛己糖,是一种还原糖,自然存在于身体和许多食物中,在高水平下,在半乳糖氧化酶的催化下,它可以转化为醛糖和过氧化氢,从而产生活性氧(ROS)。随后可能导致氧化应激、炎症、线粒体功能障碍和细胞凋亡。由于其具有方便、副作用小、存活率高而成为最受青睐的衰老模型建立药物。D-galactose is an aldohexose, a reducing sugar that occurs naturally in the body and many foods. At high levels, it can be converted into aldose and hydrogen peroxide under the catalysis of galactose oxidase. , thereby producing reactive oxygen species (ROS). This may subsequently lead to oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis. It has become the most popular drug for establishing aging models due to its convenience, small side effects, and high survival rate.
松果菊苷是一种天然苯乙烷苷,是肉苁蓉中的主要活性成分,研究表明松果菊苷在神经保护,抗肿瘤,抗衰老、心肌重塑,抗氧化、抗炎,抗凋亡方面具有有益作用。目前,尚无在猪卵母细胞体外成熟过程中联合添加松果菊苷的研究。探究添加松果菊苷能否显著提高猪卵母细胞体外成熟效率,从而提高猪卵母细胞质量,具有重要意义。Echinacea is a natural phenylethanoid glycoside and the main active ingredient in Cistanche deserticola. Studies have shown that echinacea plays a role in neuroprotection, anti-tumor, anti-aging, myocardial remodeling, antioxidant, anti-inflammation, and anti-apoptosis. has a beneficial effect. Currently, there are no studies on the combined addition of echinaceaside during the in vitro maturation of porcine oocytes. It is of great significance to explore whether the addition of echinaceaside can significantly improve the in vitro maturation efficiency of porcine oocytes, thereby improving the quality of porcine oocytes.
发明内容Contents of the invention
本发明的目的就在于为了解决上述问题而提供一种添加松果菊苷改善猪卵母细胞老化的培养液及其应用。The purpose of the present invention is to solve the above problems and provide a culture medium that adds echinacea to improve the aging of porcine oocytes and its application.
本发明通过以下技术方案来实现上述目的,一种添加松果菊苷改善猪卵母细胞老化的培养液,包括基础培养液、D-半乳糖(Sigma,G5388)和松果菊苷(MCE,HY-N0020),所述基础培养液以不含HEPES的82.9%体积分数的M199培养液(Sigma,M4530)为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清(Cellmax,SA311.01),同时补充添加1%体积分数6.9mg/mL的L-半胱氨酸(Sigma,C7880)、0.1%体积分数10μg/mL的表皮生长因子(Sigma,E4127)、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液(宁波三生),所述D-半乳糖的添加量为9mg/mL,所述松果菊苷的添加量为39.337μg/mL或78.673μg/mL,The present invention achieves the above object through the following technical solution: a culture medium that adds echinaceaside to improve the aging of porcine oocytes, including a basic culture medium, D-galactose (Sigma, G5388) and echinaside (MCE, HY-N0020), the basic culture medium is based on 82.9% volume fraction M199 culture medium (Sigma, M4530) without HEPES, with 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum added (Cellmax, SA311.01), while supplementing 1% volume fraction of 6.9 mg/mL L-cysteine (Sigma, C7880), 0.1% volume fraction of 10 μg/mL epidermal growth factor (Sigma, E4127), 1 % volume fraction of a mixture of 10 IU/mL gonadotropin and 10 IU/mL chorionic gonadotropin (Ningbo Sansheng), the added amount of D-galactose is 9 mg/mL, the added amount of echinaceaside The amount is 39.337μg/mL or 78.673μg/mL,
所述添加松果菊苷改善猪卵母细胞老化的培养液的制备方法具体为:The preparation method of the culture medium for adding echinaceaside to improve the aging of porcine oocytes is specifically:
SA、在所述基础培养液中添加9mg/mL的D-半乳糖,建立猪卵母细胞的衰老体外培养液模型;SA. Add 9 mg/mL D-galactose to the basic culture medium to establish an in vitro culture medium model of porcine oocyte aging;
SB、将5mg松果菊苷溶于127.108μL的DMSO中获得50mM的浓储液,再利用SA中制备的所述猪卵母细胞的衰老体外培养液将50mM的松果菊苷浓储液分别稀释至78.673μg/mL、39.337μg/mL;SB. Dissolve 5 mg echinaceaside in 127.108 μL of DMSO to obtain a 50mM concentrated stock solution, and then use the aging in vitro culture medium of porcine oocytes prepared in SA to dissolve the 50mM echinaceaside concentrated stock solution respectively. Dilute to 78.673μg/mL, 39.337μg/mL;
SC、向SA中制备的所述猪卵母细胞的衰老体外培养液模型中添加39.337μg/mL或78.673μg/mL松果菊苷,最终得到添加松果菊苷改善猪卵母细胞老化的培养液。SC. Add 39.337 μg/mL or 78.673 μg/mL echinacea to the aging in vitro culture medium model of porcine oocytes prepared in SA, and finally obtain a culture in which echinacea is added to improve the aging of porcine oocytes. liquid.
优选地,所述添加松果菊苷改善猪卵母细胞老化的培养液中松果菊苷的添加量为78.673μg/mL。Preferably, the amount of echinaceaside added to the culture medium for improving the aging of porcine oocytes is 78.673 μg/mL.
优选地,所述松果菊苷,其分子式为C35H45O20,其分子量为786.73,结构式如下:Preferably, the molecular formula of echinaceaside is C 35 H 45 O 20 , its molecular weight is 786.73, and its structural formula is as follows:
优选地,所述猪卵泡液的制备过程为:Preferably, the preparation process of the porcine follicular fluid is:
取猪新鲜卵巢,置于38.5℃生理盐水保温瓶中,使用18G针头注射器抽取卵巢表面卵泡的卵泡液,将抽取的卵泡液收集于15mL离心管中并放置在38.5℃恒温箱中静置30min后,收集上层卵泡液3000rpm离心30min,下层为卵丘颗粒细胞卵母细胞复合体(COCs),将离心后的上清液用0.22μm滤器过滤,将过滤后所得的猪卵泡液分装并20℃保存。Take fresh ovaries from pigs and place them in a 38.5°C physiological saline thermos. Use an 18G needle syringe to extract the follicular fluid from the follicles on the ovarian surface. Collect the extracted follicular fluid in a 15mL centrifuge tube and place it in a 38.5°C incubator for 30 minutes. , collect the upper layer of follicular fluid and centrifuge it at 3000 rpm for 30 minutes. The lower layer contains cumulus granulosa cell oocyte complexes (COCs). Filter the centrifuged supernatant with a 0.22 μm filter. The filtered porcine follicular fluid is aliquoted and stored at 20°C. save.
优选地,抽取卵泡液过程中选择直径为2~8mm的卵泡。Preferably, follicles with a diameter of 2 to 8 mm are selected during the extraction of follicular fluid.
本发明还公开一种添加松果菊苷改善猪卵母细胞老化的培养液的应用,具体为松果菊苷在提高受损猪卵母细胞成熟率和发育质量中的应用,包括对猪卵母细胞卵丘扩张程度、猪卵母细胞MII时期第一极体外排以及猪卵母细胞成熟后纺锤体和染色体形态的研究,试验设计具体为,The invention also discloses the application of a culture medium that adds echinaceaside to improve the aging of pig oocytes, specifically the application of echinaceaside in improving the maturity rate and development quality of damaged pig oocytes, including the use of echinaceaside in the aging of pig oocytes. Study on the expansion degree of mother cell cumulus, first pole efflux in porcine oocyte MII stage, and spindle and chromosome morphology after porcine oocyte maturity. The experimental design is as follows:
对照组:不含D-半乳糖和松果菊苷的体外成熟培养液Control group: in vitro maturation culture medium without D-galactose and echinacea.
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液;Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. A mixture of cystine, 0.1% epidermal growth factor with a volume fraction of 10 μg/mL, 1% gonadotropin with a volume fraction of 10 IU/mL, and chorionic gonadotropin with a volume fraction of 10 IU/mL;
D-半乳糖对照组:含9mg/mL D-半乳糖的体外成熟培养液D-galactose control group: in vitro maturation culture medium containing 9mg/mL D-galactose
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液、9mg/mL D-半乳糖;Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. Cystine, 0.1% volume fraction 10 μg/mL epidermal growth factor, 1% volume fraction 10IU/mL gonadotropin and 10IU/mL mixture of chorionic gonadotropin, 9mg/mL D-galactose;
松果菊苷组1:含39.337μg/mL松果菊苷的体外成熟培养液Echinaceaside group 1: in vitro maturation culture medium containing 39.337μg/mL echinaceaside
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液、9mg/mL D-半乳糖、39.337μg/mL的松果菊苷;Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. Cystine, 0.1% volume fraction 10 μg/mL epidermal growth factor, 1% volume fraction 10 IU/mL gonadotropin and 10 IU/mL mixture of chorionic gonadotropin, 9 mg/mL D-galactose, 39.337 μg /mL of echinaceaside;
松果菊苷组2:含78.673μg/mL松果菊苷的体外成熟培养液Echinaceaside group 2: in vitro maturation culture medium containing 78.673μg/mL echinaceaside
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液、9mg/mL D-半乳糖、78.673μg/mL的松果菊苷。Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. Cystine, 0.1% volume fraction 10 μg/mL epidermal growth factor, 1% volume fraction 10 IU/mL gonadotropin and 10 IU/mL mixture of chorionic gonadotropin, 9 mg/mL D-galactose, 78.673 μg /mL of echinaceaside.
优选地,所述猪卵母细胞卵丘扩张程度、猪卵母细胞MII时期第一极体外排的研究试验中,设置对照组、D-半乳糖对照组、松果菊苷组1、松果菊苷组2,进行三次独立重复试验,每次重复检测60枚MII期卵母细胞,培养42-48h;在猪卵母细胞成熟后纺锤体和染色体形态的研究试验中,取消松果菊苷组1,保留对照组、D-半乳糖对照组和松果菊苷组2,每组试验均设置三次独立重复,每次重复检测15~20枚MI期卵母细胞,培养24-28h,结果差异性统计使用GraphPad Prism统计软件分析。Preferably, in the research experiment on the degree of cumulus expansion of porcine oocytes and the excretion of the first pole of porcine oocytes in the MII stage, a control group, a D-galactose control group, an echinaceaside group 1, and an echinacea group are set. Echinaceaside group 2, conducted three independent repeated experiments, each repeated testing of 60 MII stage oocytes, cultured for 42-48h; in the research experiment on the spindle and chromosome morphology of porcine oocytes after maturation, echinaceaside was eliminated Group 1, retain the control group, D-galactose control group and echinacea glycoside group 2. Each group of experiments is set up with three independent repetitions. Each repetition detects 15-20 MI stage oocytes and culture them for 24-28 hours. The results Difference statistics were analyzed using GraphPad Prism statistical software.
本发明的有益效果是:与现有技术相比,本发明提供了一种添加松果菊苷改善猪卵母细胞老化的培养液及其应用,通过在基础培养液中添加9mg/mLD-半乳糖建立损伤模型,并在此基础上同时添加78.673μg/mL的松果菊苷,可显著提高卵母细胞的成熟率,成熟率提高近20%,纺锤体正常比例提高近26%,该方案可有效获得大量高质量卵母细胞,为体外受精、孤雌激活、核移植制备克隆胚胎等技术提供支持,并在良种家畜扩繁、动物模型构建、转基因动物生产等方面发挥重要意义。The beneficial effects of the present invention are: compared with the prior art, the present invention provides a culture medium that adds echinacea to improve the aging of porcine oocytes and its application. By adding 9 mg/mLD-half to the basic culture medium, Establishing a lactose injury model, and adding 78.673 μg/mL echinaceaside at the same time can significantly improve the maturation rate of oocytes by nearly 20%, and the normal proportion of spindles by nearly 26%. This program It can effectively obtain a large number of high-quality oocytes, provide support for technologies such as in vitro fertilization, parthenogenetic activation, and nuclear transfer to prepare cloned embryos, and play an important role in the propagation of fine livestock, construction of animal models, and production of transgenic animals.
附图说明Description of the drawings
图1为本发明猪卵母细胞体外成熟过程中培养液中添加或不添加松果菊苷的猪卵母细胞卵丘扩张程度:依次为对照组、D-半乳糖对照组、松果菊苷组1(39.337μg/mL)、松果菊苷组2(78.673μg/mL);原始图片比例尺为200μm;放大后图片比例尺为50μm。Figure 1 shows the degree of cumulus expansion of porcine oocytes with or without echinaceaside added to the culture medium during the in vitro maturation of porcine oocytes of the present invention: the control group, the D-galactose control group, and the echinaceaside in that order. Group 1 (39.337 μg/mL), echinaceaside group 2 (78.673 μg/mL); the scale bar of the original picture is 200 μm; the scale bar of the enlarged picture is 50 μm.
图2为本发明猪卵母细胞体外成熟过程中培养液中添加或不添加松果菊苷猪卵母细胞MII时期第一极体外排情况;Figure 2 shows the efflux of the first pole in the MII stage of porcine oocytes in the culture medium with or without the addition of echinaceaside during the in vitro maturation process of porcine oocytes of the present invention;
其中,A为对照组、D-半乳糖对照组、松果菊苷组1(基础培养液中添加39.337μg/mL松果菊苷)、松果菊苷组2(基础培养液中添加78.673μg/mL松果菊苷)MI期猪卵母细胞第一极体外排情况,箭头所指为第一极体;原始图片比例尺为200μm;放大后图片比例尺为50μm。Among them, A is the control group, D-galactose control group, echinaceaside group 1 (39.337 μg/mL echinaceaside is added to the basal culture medium), and echinaceaside group 2 (78.673 μg is added to the basal culture medium). /mL Echinaceaside) The first polar efflux of porcine oocytes in the MI stage. The arrow points to the first polar body. The scale bar of the original image is 200 μm; the scale bar of the enlarged image is 50 μm.
B为对照组、D-半乳糖对照组、松果菊苷组1(基础培养液中添加39.337μg/mL松果菊苷)、松果菊苷组2(基础培养液中添加78.673μg/mL松果菊苷)MI期猪卵母细胞第一极体外排百分比。B is the control group, D-galactose control group, echinaceaside group 1 (39.337 μg/mL echinaceaside is added to the basal culture medium), and echinacoside group 2 (78.673 μg/mL is added to the basal culture medium). Echinaceaside) Percentage of first pole efflux of porcine oocytes at MI stage.
图3为本发明猪卵母细胞体外成熟过程中培养液中添加或不添加松果菊苷猪卵母细胞成熟后纺锤体和染色体形态情况;Figure 3 shows the spindle and chromosome morphology of mature porcine oocytes with or without echinaceaside added to the culture medium during the in vitro maturation process of porcine oocytes of the present invention;
其中,A为对照组、D-半乳糖对照组、松果菊苷组2(基础培养液中添加78.673μg/mL松果菊苷)MI期猪卵母细胞纺锤体形态情况,使用共聚焦显微镜拍照;比例尺为20μm;Among them, A is the spindle morphology of MI stage porcine oocytes in the control group, D-galactose control group, and echinaceaside group 2 (78.673 μg/mL echinaceaside was added to the basal culture medium), using a confocal microscope Photographed; scale bar is 20 μm;
B为对照组、D-半乳糖对照组、松果菊苷组2(基础培养液中添加78.673μg/mL松果菊苷)MI期猪卵母细胞纺锤体形态正常比例百分比;B is the percentage of normal spindle morphology of MI stage porcine oocytes in the control group, D-galactose control group, and echinaceaside group 2 (78.673 μg/mL echinaceaside was added to the basal culture medium);
具体实施方式Detailed ways
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only some of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts fall within the scope of protection of the present invention.
本发明中所使用到的试剂如下:The reagents used in the present invention are as follows:
D-半乳糖:购自Sigma,型号为:G5388;D-galactose: purchased from Sigma, model number: G5388;
松果菊苷:购自MCE,型号为:HY-N0020;Echinaceaside: purchased from MCE, model: HY-N0020;
M199培养液:购自Sigma,型号为:M4530;M199 culture medium: purchased from Sigma, model: M4530;
5%体积分数的胎牛血清:购自Cellmax,型号为:SA311.01;5% volume fraction of fetal bovine serum: purchased from Cellmax, model: SA311.01;
L-半胱氨酸:购自Sigma,型号为:C7880;L-cysteine: purchased from Sigma, model: C7880;
表皮生长因子:购自Sigma,型号为:E4127;Epidermal growth factor: purchased from Sigma, model number: E4127;
促性腺激素和绒毛膜促性激素的混合液:购自宁波三生;Mixed solution of gonadotropin and chorionic gonadotropin: purchased from Ningbo Sansheng;
透明质酸酶溶液:购自Sigma,型号为:H3506;Hyaluronidase solution: purchased from Sigma, model: H3506;
anti-α-tubulin-FITC:购自Sigma,型号为:F2168);anti-α-tubulin-FITC: purchased from Sigma, model: F2168);
固定液:购自Sigma,型号为:818715;Fixative: purchased from Sigma, model number: 818715;
透化液:购自索莱宝,型号为:9002-93-1;Permeabilizing fluid: purchased from Solebao, model number: 9002-93-1;
封闭液:购自Sigma,型号为:A1933;Blocking solution: purchased from Sigma, model: A1933;
washing buffer:购自碧云天,型号为P0106;washing buffer: purchased from Biyuntian, model P0106;
Hoechst 33342:购自赛默飞,型号为2189158。Hoechst 33342: purchased from Thermo Fisher, model number 2189158.
本发明所使用到的仪器设备如下:The instruments and equipment used in this invention are as follows:
体式显微镜:购自奥林巴斯,型号为SZX7;Stereo microscope: purchased from Olympus, model SZX7;
共聚焦显微镜:购自Olympus,型号FV3000。Confocal microscope: purchased from Olympus, model FV3000.
实施例1添加松果菊苷改善猪卵母细胞老化的培养液及其制备方法Example 1 Adding echinaceaside to culture medium to improve aging of porcine oocytes and its preparation method
一种添加松果菊苷改善猪卵母细胞老化的培养液,包括基础培养液、D-半乳糖和松果菊苷,所述基础培养液以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液,所述D-半乳糖的添加量为9mg/mL,所述松果菊苷的添加量为39.337μg/mL或78.673μg/mL。A culture medium that adds echinaceaside to improve the aging of porcine oocytes, including a basic culture medium, D-galactose and echinaceaside. The base culture medium is an 82.9% volume fraction M199 culture medium that does not contain HEPES. As a base, add 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum. At the same time, add 1% volume fraction of L-cysteine at 6.9 mg/mL and 0.1% volume fraction of epidermis at 10 μg/mL. A mixed solution of growth factors, 1% volume fraction of gonadotropins and 10 IU/mL of chorionic gonadotropin, the added amount of D-galactose is 9 mg/mL, and the added amount of echinaceaside is 39.337μg/mL or 78.673μg/mL.
所述添加松果菊苷改善猪卵母细胞老化的培养液的制备方法具体为:The preparation method of the culture medium for adding echinaceaside to improve the aging of porcine oocytes is specifically:
SA、在所述基础培养液中添加9mg/mL的D-半乳糖,建立猪卵母细胞的衰老体外培养液模型;SA. Add 9 mg/mL D-galactose to the basic culture medium to establish an in vitro culture medium model of porcine oocyte aging;
SB、将5mg松果菊苷溶于127.108μL的DMSO中获得50mM的浓储液,再利用SA中制备的所述猪卵母细胞的衰老体外培养液将50mM的松果菊苷浓储液分别稀释至78.673μg/mL、39.337μg/mL;SB. Dissolve 5 mg echinaceaside in 127.108 μL of DMSO to obtain a 50mM concentrated stock solution, and then use the aging in vitro culture medium of porcine oocytes prepared in SA to dissolve the 50mM echinaceaside concentrated stock solution respectively. Dilute to 78.673μg/mL, 39.337μg/mL;
SC、向SA中制备的所述猪卵母细胞的衰老体外培养液模型中添加39.337μg/mL或78.673μg/mL松果菊苷,最终得到添加松果菊苷改善猪卵母细胞老化的培养液。SC. Add 39.337 μg/mL or 78.673 μg/mL echinacea to the aging in vitro culture medium model of porcine oocytes prepared in SA, and finally obtain a culture in which echinacea is added to improve the aging of porcine oocytes. liquid.
上述实施例中,所述松果菊苷,其分子式为C35H45O20,其分子量为786.73,结构式如下:In the above embodiments, the molecular formula of echinaceaside is C 35 H 45 O 20 , its molecular weight is 786.73, and its structural formula is as follows:
上述实施例中,猪卵泡液的制备过程具体为:In the above embodiment, the preparation process of porcine follicular fluid is specifically as follows:
取猪新鲜卵巢,置于38.5℃生理盐水保温瓶中,使用18G针头注射器抽取卵巢表面卵泡的卵泡液,抽取卵泡液过程中选择直径为2~8mm的卵泡,将抽取的卵泡液收集于15mL离心管中并放置在38.5℃恒温箱中静置30min后,收集上层卵泡液3000rpm离心30min,下层为卵丘颗粒细胞卵母细胞复合体(COCs),将离心后的上清液用0.22μm滤器过滤,将过滤后所得的猪卵泡液分装并20℃保存。Take fresh ovaries from pigs and place them in a 38.5°C physiological saline thermos. Use an 18G needle syringe to extract the follicular fluid from the follicles on the ovarian surface. During the process of extracting follicular fluid, select follicles with a diameter of 2 to 8 mm. Collect the extracted follicular fluid in a 15 mL centrifuge. tube and placed in a 38.5°C incubator for 30 minutes. The upper layer of follicular fluid was collected and centrifuged at 3000 rpm for 30 minutes. The lower layer was cumulus granulosa cell oocyte complexes (COCs). The centrifuged supernatant was filtered with a 0.22 μm filter. , aliquot the filtered porcine follicular fluid and store it at 20°C.
实施例2添加松果菊苷改善猪卵母细胞老化的培养液的应用Example 2 Application of adding echinacea to culture medium to improve aging of porcine oocytes
2.1试验设计2.1 Experimental design
对照组:不含D-半乳糖和松果菊苷的体外成熟培养液Control group: in vitro maturation culture medium without D-galactose and echinacea.
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液;Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. A mixture of cystine, 0.1% epidermal growth factor with a volume fraction of 10 μg/mL, 1% gonadotropin with a volume fraction of 10 IU/mL, and chorionic gonadotropin with a volume fraction of 10 IU/mL;
D-半乳糖对照组:含9mg/mL D-半乳糖的体外成熟培养液D-galactose control group: in vitro maturation culture medium containing 9mg/mL D-galactose
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液、9mg/mL D-半乳糖;Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. Cystine, 0.1% volume fraction 10 μg/mL epidermal growth factor, 1% volume fraction 10IU/mL gonadotropin and 10IU/mL mixture of chorionic gonadotropin, 9mg/mL D-galactose;
松果菊苷组1:含39.337μg/mL松果菊苷的体外成熟培养液Echinaceaside group 1: in vitro maturation culture medium containing 39.337μg/mL echinaceaside
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液、9mg/mL D-半乳糖、39.337μg/mL的松果菊苷;Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. Cystine, 0.1% volume fraction 10 μg/mL epidermal growth factor, 1% volume fraction 10 IU/mL gonadotropin and 10 IU/mL mixture of chorionic gonadotropin, 9 mg/mL D-galactose, 39.337 μg /mL of echinaceaside;
松果菊苷组2:含78.673μg/mL松果菊苷的体外成熟培养液Echinaceaside group 2: in vitro maturation culture medium containing 78.673μg/mL echinaceaside
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液、9mg/mL D-半乳糖、78.673μg/mL的松果菊苷。Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. Cystine, 0.1% volume fraction 10 μg/mL epidermal growth factor, 1% volume fraction 10 IU/mL gonadotropin and 10 IU/mL mixture of chorionic gonadotropin, 9 mg/mL D-galactose, 78.673 μg /mL of echinaceaside.
2.2对猪卵母细胞卵丘扩张程度以及猪卵母细胞MII时期第一极体外排的研究2.2 Research on the degree of cumulus expansion of porcine oocytes and the efflux of the first pole of porcine oocytes during the MII stage
2.2.1猪卵母细胞前期处理2.2.1 Preliminary treatment of pig oocytes
取猪新鲜卵巢,置于38.5℃生理盐水保温瓶中,使用18G针头注射器抽取卵巢表面卵泡的卵泡液,抽取卵泡液过程中选择直径为2~8mm的卵泡,将抽取的卵泡液收集于15mL离心管中并放置在38.5℃恒温箱中静置30min,静置后上层为卵泡液,下层为卵丘颗粒细胞卵母细胞复合体(COCs),舍弃上层卵泡液,留下下层COCs,添加与沉淀物等体积的DPBS作为猪卵母细胞操作液,颠倒混匀,倒入60mm培养皿中,在体式显微镜下进行挑选,使用500μm玻璃针选择卵丘细胞三层及三层以上的COCs,在不含松果菊苷和D-半乳糖的体外成熟培养液中洗涤三次,移入对照或松果菊苷组进行成熟培养。Take fresh ovaries from pigs and place them in a 38.5°C physiological saline thermos. Use an 18G needle syringe to extract the follicular fluid from the follicles on the ovarian surface. During the process of extracting follicular fluid, select follicles with a diameter of 2 to 8 mm. Collect the extracted follicular fluid in a 15 mL centrifuge. tube and place it in a 38.5°C incubator for 30 minutes. After standing, the upper layer is follicular fluid and the lower layer is cumulus granulosa cell oocyte complex (COCs). The upper layer of follicular fluid is discarded, leaving the lower layer of COCs. Add and precipitate Use an equal volume of DPBS as the porcine oocyte operating fluid, mix by inversion, pour into a 60mm petri dish, select under a stereomicroscope, use a 500μm glass needle to select COCs with three or more layers of cumulus cells. Wash three times in in vitro maturation culture medium containing echinaceaside and D-galactose, and then move to the control or echinaceaside group for maturation culture.
2.2.2猪卵母细胞体外成熟培养2.2.2 In vitro maturation culture of porcine oocytes
对照组:将不含松果菊苷和D-半乳糖的体外成熟培养液加入到4孔板,每一个孔加入500μL培养液,上覆石蜡油300μL,在38.5℃、5%CO2、饱和湿度的培养箱中预热5h以上,将挑选并洗涤后的COCs放置于成熟孔中,每孔60枚,培养42-48h。Control group: Add in vitro maturation culture medium without echinaceaside and D-galactose to a 4-well plate, add 500 μL of culture medium to each well, cover with 300 μL of paraffin oil, and incubate at 38.5°C, 5% CO 2 , saturated Preheat in a humid incubator for more than 5 hours, place the selected and washed COCs in mature wells, 60 COCs per well, and culture for 42-48 hours.
D-半乳糖对照组:将含9mg/mL D-半乳糖的体外成熟培养液加入到4孔板,每一个孔加入500μL培养液,上覆石蜡油300μL,在38.5℃、5%CO2、饱和湿度的培养箱中预热5h以上,将挑选并洗涤后的COCs放置于成熟孔中,每孔60枚,培养42-48h。D-galactose control group: Add the in vitro maturation culture medium containing 9 mg/mL D-galactose to a 4-well plate, add 500 μL of culture medium to each well, cover with 300 μL of paraffin oil, and incubate at 38.5°C, 5% CO 2 , Preheat in an incubator with saturated humidity for more than 5 hours. Place the selected and washed COCs in mature wells, 60 COCs per well, and culture for 42-48 hours.
松果菊苷组1:将含9mg/mL D-半乳糖和39.337μg/mL松果菊苷的体外成熟培养液加入到4孔板,每一个孔加入500μL培养液,上覆石蜡油300μL,在38.5℃、5%CO2、饱和湿度的培养箱中预热5h以上,将挑选并洗涤后的COCs放置于成熟孔中,每孔60枚,培养42-48h。Echinacea group 1: Add the in vitro maturation culture medium containing 9 mg/mL D-galactose and 39.337 μg/mL echinacea to a 4-well plate, add 500 μL of culture medium to each well, and cover with 300 μL of paraffin oil. Preheat for more than 5 hours in an incubator at 38.5°C, 5% CO 2 and saturated humidity. Place the selected and washed COCs in mature wells, 60 pieces per well, and culture them for 42-48 hours.
松果菊苷组2:将含9mg/mL D-半乳糖和78.673μg/mL松果菊苷的体外成熟培养液加入到4孔板,每一个孔加入500μL培养液,上覆石蜡油300μL,38.5℃、5%CO2、饱和湿度的培养箱中预热5h以上,将挑选并洗涤后的COCs放置于成熟孔中,每孔60枚,培养42-48h。Echinacea group 2: Add the in vitro maturation culture medium containing 9 mg/mL D-galactose and 78.673 μg/mL echinacea to a 4-well plate, add 500 μL of culture medium to each well, and cover with 300 μL of paraffin oil. Preheat in an incubator at 38.5°C, 5% CO 2 and saturated humidity for more than 5 hours. Place the selected and washed COCs in mature wells, 60 pieces per well, and culture them for 42-48 hours.
2.2.3MII猪期卵母细胞收集2.2.3 MII porcine oocyte collection
使用TCM-199为溶剂配制浓度为1mg/mL的透明质酸酶溶液,利用口径200μm的玻璃针吸取培养成熟的COCs并放入200μL 1mg/mL的透明质酸酶溶液中,并用100μL的移液枪轻轻吹打,直到体式显微镜下可见充分脱去卵丘颗粒的卵母细胞,用200μm玻璃针转移卵母细胞至TCM-199溶液中洗涤三次,每次洗涤需在洁净的TCM-199中进行,之后在体式显微镜下用200μm玻璃针挑选排出第一极体的卵母细胞,即为成熟的MII期卵母细胞。Use TCM-199 as the solvent to prepare a hyaluronidase solution with a concentration of 1 mg/mL. Use a glass needle with a diameter of 200 μm to absorb the mature COCs and put them into 200 μL of the 1 mg/mL hyaluronidase solution, and use a 100 μL pipette Gently blow with the gun until the oocytes with sufficient cumulus granules can be seen under the stereomicroscope. Use a 200 μm glass needle to transfer the oocytes to the TCM-199 solution and wash them three times. Each wash must be performed in clean TCM-199. , and then use a 200 μm glass needle under a stereomicroscope to select the oocytes that discharge the first polar body, which are the mature MII stage oocytes.
以上方法在对照组、D-半乳糖对照组、松果菊苷组1和松果菊苷组2中均适用。The above method is applicable to the control group, D-galactose control group, echinaceaside group 1 and echinaceaside group 2.
成熟率=排出第一极体的卵母细胞数(MII期)/卵母细胞总数。Maturation rate = number of oocytes expelling the first polar body (MII stage)/total number of oocytes.
表1不同试验组中MII期卵母细胞成熟率Table 1 MII stage oocyte maturation rate in different experimental groups
结果如图1、图2所示,与D-半乳糖对照组相比,当培养液中添加78.673μg/mL松果菊苷时,成熟率显著提升,且卵丘细胞扩展程度更充分,卵母细胞MII时期第一极体外排出更加明显。The results are shown in Figures 1 and 2. Compared with the D-galactose control group, when 78.673 μg/mL echinacea was added to the culture medium, the maturation rate was significantly increased, and the cumulus cells expanded more fully, and the eggs In the MII stage of the mother cell, the first pole is excreted more obviously.
试验结果表明,在基础培养液中添加78.673μg/mL的松果菊苷的效果较好,后续试验中以松果菊苷组2中的松果菊苷含量进行添加。The test results showed that adding 78.673 μg/mL echinaceaside to the basic culture medium had a better effect. In subsequent tests, the content of echinaside in group 2 was used to add echinaside.
2.3对猪卵母细胞成熟后纺锤体和染色体形态的研究2.3 Study on the spindle and chromosome morphology of mature porcine oocytes
2.3.1试验设计2.3.1 Experimental design
对照组:不含D-半乳糖和松果菊苷的体外成熟培养液Control group: in vitro maturation culture medium without D-galactose and echinacea.
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液;Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. A mixture of cystine, 0.1% epidermal growth factor with a volume fraction of 10 μg/mL, 1% gonadotropin with a volume fraction of 10 IU/mL, and chorionic gonadotropin with a volume fraction of 10 IU/mL;
D-半乳糖对照组:含9mg/mL D-半乳糖的体外成熟培养液D-galactose control group: in vitro maturation culture medium containing 9mg/mL D-galactose
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液、9mg/mL D-半乳糖;Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. Cystine, 0.1% volume fraction 10 μg/mL epidermal growth factor, 1% volume fraction 10IU/mL gonadotropin and 10IU/mL mixture of chorionic gonadotropin, 9mg/mL D-galactose;
松果菊苷组2:含78.673μg/mL松果菊苷的体外成熟培养液Echinaceaside group 2: in vitro maturation culture medium containing 78.673μg/mL echinaceaside
以不含HEPES的82.9%体积分数的M199培养液为基础,添加10%体积分数的猪卵泡液,以及5%体积分数的胎牛血清,同时补充添加1%体积分数6.9mg/mL的L半胱氨酸、0.1%体积分数10μg/mL的表皮生长因子、1%体积分数10IU/mL的促性腺激素和10IU/mL的绒毛膜促性激素的混合液、9mg/mL D-半乳糖、78.673μg/mL的松果菊苷。Based on the HEPES-free 82.9% volume fraction M199 culture medium, 10% volume fraction of porcine follicular fluid and 5% volume fraction of fetal bovine serum were added, and at the same time, 1% volume fraction of L-half at 6.9 mg/mL was added. Cystine, 0.1% volume fraction 10 μg/mL epidermal growth factor, 1% volume fraction 10 IU/mL gonadotropin and 10 IU/mL mixture of chorionic gonadotropin, 9 mg/mL D-galactose, 78.673 μg /mL of echinaceaside.
上述对照组、D-半乳糖对照组和松果菊苷组2均设置三组重复,每组重复检测15~20枚MI期卵母细胞,结果差异性统计使用GraphPad Prism统计软件分析。The above control group, D-galactose control group and echinacea glycoside group 2 were all set up in three repeated groups, and 15 to 20 MI stage oocytes were repeatedly detected in each group. The difference statistics of the results were analyzed using GraphPad Prism statistical software.
2.3.2猪卵母细胞体外成熟培养2.3.2 In vitro maturation culture of porcine oocytes
参考上述实施例2.2.2。Refer to the above embodiment 2.2.2.
2.3.3MI期卵母细胞收集2.3.3 MI stage oocyte collection
使用TCM-199为溶剂配制浓度为1mg/mL的透明质酸酶溶液,利用口径200μm的玻璃针吸取培养24-28h的COCs放入200μL 1mg/mL的透明质酸酶溶液中,并用100μL的移液枪轻轻吹打,直到镜下可见充分脱去卵丘颗粒的卵母细胞,用玻璃针转移卵母细胞至TCM-199溶液中洗涤三次,每次洗涤需在洁净的TCM-199中进行,所得细胞即为MI期卵母细胞。Use TCM-199 as the solvent to prepare a hyaluronidase solution with a concentration of 1 mg/mL. Use a glass needle with a diameter of 200 μm to absorb the COCs cultured for 24-28 h and put them into 200 μL of the 1 mg/mL hyaluronidase solution, and use a 100 μL pipette. Gently blow with the liquid gun until the oocytes with fully stripped cumulus granules can be seen under the microscope. Use a glass needle to transfer the oocytes to the TCM-199 solution and wash them three times. Each wash must be carried out in clean TCM-199. The resulting cells are MI stage oocytes.
以上方法在对照组、D-半乳糖对照组和松果菊苷组2中均适用。The above method is applicable to the control group, D-galactose control group and echinacea glycoside group 2.
2.3.4猪卵母细胞纺锤体、染色体形态检测2.3.4 Detection of spindle and chromosome morphology of porcine oocytes
猪成熟卵母细胞纺锤体、染色体形态检测使用anti-α-tubulin-FITC进行染色,将对照组、D-半乳糖对照组和松果菊苷组2中获取的MI期卵母细胞分别在固定液中室温静置30min,洗涤液洗涤三次,并移入透化液中室温静置8h。之后移入封闭液中室温静置1h,将室温静置后的对照组、D-半乳糖对照组和松果菊苷组2中MI期卵母细胞分别放置于含有anti-α-tubulin-FITC(1:800)的溶液中,在湿盒中于4℃过夜孵育,之后将MI期卵母细胞用washing buffer洗涤三次,每次不少于3min,利用Hoechst 33342对细胞核进行染色,在共聚焦显微镜下观察。结果见图3。Anti-α-tubulin-FITC was used to detect the spindle and chromosome morphology of mature porcine oocytes. MI stage oocytes obtained from the control group, D-galactose control group and echinacea group 2 were fixed in The solution was left to stand at room temperature for 30 minutes, washed three times with washing solution, and then transferred to permeabilization solution and left to stand at room temperature for 8 hours. Afterwards, they were moved to the blocking solution and left to stand at room temperature for 1 hour. The MI stage oocytes in the control group, D-galactose control group and echinacea group 2 after standing at room temperature were placed in a container containing anti-α-tubulin-FITC ( 1:800) solution, incubate overnight at 4°C in a humidified box, then wash the MI stage oocytes three times with washing buffer, no less than 3 minutes each time, use Hoechst 33342 to stain the nuclei, and use a confocal microscope to Observe below. The results are shown in Figure 3.
由图3可知,对照组中纺锤体正常率为70.07±2.754%;D-半乳糖对照组中纺锤体正常率为30.60±7.002%;松果菊苷组2中纺锤体正常率为57.13±7.150%,与D-半乳糖对照组相比,当猪卵母细胞基础培养液中添78.673μg/mL松果菊苷时,纺锤体正常率显著升高,纺锤体形态明显改善,纺锤体正常率提高约26%,同时染色体排列紊乱程度降低。As can be seen from Figure 3, the normal spindle rate in the control group was 70.07±2.754%; the normal spindle rate in the D-galactose control group was 30.60±7.002%; the normal spindle rate in the echinacea group 2 was 57.13±7.150 %, compared with the D-galactose control group, when 78.673 μg/mL echinaceaside was added to the porcine oocyte basal culture medium, the spindle normal rate significantly increased, the spindle morphology was significantly improved, and the spindle normal rate The increase was about 26%, while the degree of chromosome arrangement disorder was reduced.
综上所述,本发明提供了一种添加松果菊苷改善猪卵母细胞老化的培养液及其应用,通过在基础培养液中添加9mg/mLD-半乳糖建立损伤模型,并在此基础上同时添加78.673μg/mL的松果菊苷,可显著提高卵母细胞的成熟率,成熟率提高近20%,纺锤体正常比例提高近26%,该方案可有效获得大量高质量卵母细胞,为体外受精、孤雌激活、核移植制备克隆胚胎等技术提供支持,并在良种家畜扩繁、动物模型构建、转基因动物生产等方面发挥重要意义。In summary, the present invention provides a culture medium that adds echinaceaside to improve the aging of porcine oocytes and its application. The damage model is established by adding 9 mg/mL D-galactose to the basic culture medium, and on this basis The addition of 78.673 μg/mL echinaceaside can significantly increase the maturation rate of oocytes by nearly 20%, and the normal proportion of spindles by nearly 26%. This program can effectively obtain a large number of high-quality oocytes. , provides support for technologies such as in vitro fertilization, parthenogenetic activation, and nuclear transfer to prepare cloned embryos, and plays an important role in the expansion of breeding livestock, construction of animal models, and production of transgenic animals.
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。不应将权利要求中的任何附图标记视为限制所涉及的权利要求。It is obvious to those skilled in the art that the present invention is not limited to the details of the above-described exemplary embodiments, and that the present invention can be implemented in other specific forms without departing from the spirit or essential characteristics of the present invention. Therefore, the embodiments should be regarded as illustrative and non-restrictive from any point of view, and the scope of the present invention is defined by the appended claims rather than the above description, and it is therefore intended that all claims falling within the claims All changes within the meaning and scope of equivalent elements are included in the present invention. Any reference signs in the claims shall not be construed as limiting the claim in question.
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。In addition, it should be understood that although this specification is described in terms of implementations, not each implementation only contains an independent technical solution. This description of the specification is only for the sake of clarity, and those skilled in the art should take the specification as a whole. , the technical solutions in each embodiment can also be appropriately combined to form other implementations that can be understood by those skilled in the art.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311212065.8A CN117264878A (en) | 2023-09-19 | 2023-09-19 | Culture solution added with echinacoside for improving porcine oocyte aging and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311212065.8A CN117264878A (en) | 2023-09-19 | 2023-09-19 | Culture solution added with echinacoside for improving porcine oocyte aging and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117264878A true CN117264878A (en) | 2023-12-22 |
Family
ID=89213652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311212065.8A Pending CN117264878A (en) | 2023-09-19 | 2023-09-19 | Culture solution added with echinacoside for improving porcine oocyte aging and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117264878A (en) |
-
2023
- 2023-09-19 CN CN202311212065.8A patent/CN117264878A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shuttleworth et al. | In vitro development of pig preantral follicles cultured in a serum-free medium and the effect of angiotensin II | |
Alm et al. | In vitro maturation of horse oocytes | |
CN118406637A (en) | Additive for promoting quality of in-vitro mature bovine oocytes, culture solution and application of additive | |
Bizarro-Silva et al. | Influence of follicle-stimulating hormone concentrations on the integrity and development of bovine follicles cultured in vitro | |
Hassan et al. | Effect of alpha lipoic acid as an antioxidant supplement during in vitro maturation medium on bovine embryonic development | |
Bian et al. | Vitreous cryopreservation of human preantral follicles encapsulated in alginate beads with mini mesh cups | |
Le et al. | Agarose-based 3D culture improved the developmental competence of oocyte-granulosa complex isolated from porcine preantral follicle | |
Matos et al. | In vitro development of primordial follicles after long-term culture of goat ovarian tissue | |
Agung et al. | In vitro fertilization and development of porcine oocytes matured in follicular fluid | |
CN117264878A (en) | Culture solution added with echinacoside for improving porcine oocyte aging and application thereof | |
CN103074296A (en) | In vitro maturation method and in vitro maturation culture solution for mouse naked ovum | |
Malenko et al. | A new simple and reliable vitrification device based on Hollow Fiber Vitrification (HFV) method evaluated using IVP bovine embryos | |
CN109897820B (en) | Method for delaying aging of in vitro cultured ovum | |
CN118256426A (en) | Complete culture medium for establishing oogonial stem cell line of Scorpio humilis and its application | |
CN111759864A (en) | Application of amniotic fluid stem cells in the preparation of drugs for the treatment of lupus nephritis | |
García-Ferreyra et al. | High pregnancy and implantation rates can be obtained using magnetic-activated cell sorting (MACS) to selection spermatozoa in patients with high levels of spermatic DNA fragmentation | |
Hatakeyama et al. | Assisted sperm fusion insemination improves fertilization rates and increases usable embryos for transfer: a clinical sibling-oocyte study | |
Silva et al. | The Influence of Oxygen Tension on Cumulus Cell Viability of Canine COCs Matured in High‐Glucose Medium | |
Yin et al. | Comparative maturation of cynomolgus monkey oocytes in vivo and in vitro | |
CN114410573A (en) | A kind of oocyte in vitro maturation medium additive and its application | |
Shang et al. | Effect of β-mercaptoethanol and buffalo follicular fluid on fertilization and subsequent embryonic development of water buffalo (Bubalus bubalis) oocytes derived from in vitro maturation | |
Bryła et al. | Analysis of in vivo-and in vitro-derived pig expanded blastocysts based on DNA fragmentation | |
Brück et al. | Morphology of the oocyte-follicular connection in the mare | |
CN102258004B (en) | Method for preserving/culturing oocytes in vitro to inhibit oocytes from germinal vesicle breakdown | |
Mardenli et al. | Effectiveness of ovine follicular fluid and ewe age on in vitro nuclear maturation and embryo evolution of awassi ewes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |